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http://dx.doi.org/10.1016/j.ccr.2013.02.024SUMMARYDNA damage elicits a cellular signaling response that initiates cell cycle arrest and DNA repair. Here, we find
that DNA damage triggers a critical block in glutamine metabolism, which is required for proper DNA damage
responses. This block requires themitochondrial SIRT4,which is induced by numerous genotoxic agents and
represses themetabolism of glutamine into tricarboxylic acid cycle. SIRT4 loss leads to both increased gluta-
mine-dependent proliferation and stress-induced genomic instability, resulting in tumorigenic phenotypes.
Moreover, SIRT4 knockout mice spontaneously develop lung tumors. Our data uncover SIRT4 as an impor-
tant component of the DNA damage response pathway that orchestrates a metabolic block in glutamine
metabolism, cell cycle arrest, and tumor suppression.INTRODUCTION
DNA damage initiates a tightly coordinated signaling response to
maintain genomic integrity by promoting cell cycle arrest and
DNA repair. Upon DNA damage, ataxia telangiectasia mutated
(ATM) and ataxia telangiectasia and RAD3-related protein
(ATR) are activated and induce phosphorylation of CHK1,
CHK2, and g-H2AX to trigger cell cycle arrest and to initiate
assembly of DNA damage repair machinery (Abraham, 2001;
Ciccia and Elledge, 2010; Su, 2006). Cell cycle arrest is a critical
outcome of the DNA damage response (DDR), and defects in the
DDR often lead to increased incorporation of mutations into
newly synthesized DNA, the accumulation of chromosomal
instability, and tumor development (Abbas and Dutta, 2009;
Deng, 2006; Negrini et al., 2010).Significance
Genomic instability and altered metabolism are key features
involved in regulating DNA damage responses and metabolic
ment of strategies to prevent or treat cancer. We find that SI
suppressor by regulatingmetabolic responses to DNAdamage
tantly, we also show that SIRT4 knockout mice spontaneousl
decreased in many human cancers. Our findings suggest that
450 Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc.The cellular metabolic response to DNA damage is not well
elucidated. Recently, it has been shown that DNA damage
causes cells to upregulate the pentose phosphate pathway
(PPP) to generate nucleotide precursors needed for DNA repair
(Cosentino et al., 2011). Intriguingly, a related metabolic switch
to increase anabolic glucose metabolism has been observed
for tumor cells and is an important component of rapid gener-
ation of biomass for cell growth and proliferation (Jones and
Thompson, 2009; Koppenol et al., 2011). Hence, cells exposed
to genotoxic stress face a metabolic challenge; they must be
able to upregulate nucleotide biosynthesis to facilitate DNA
repair, while at the same time limiting proliferation and inducing
cell cycle arrest to limit the accumulation of damaged DNA. The
molecular events that regulate this specific metabolic program
in response to DNA damage are still unclear.of many cancer cells. Thus, defining the factors that are
processes may have profound implications for the develop-
RT4, a mitochondria-localized sirtuin, functions as a tumor
and repressingmitochondrial glutaminemetabolism. Impor-
y develop several types of tumors and SIRT4 expression is
SIRT4 may be a potential therapeutic target against tumors.
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SIRT4 Functions as a Tumor SuppressorSirtuins are a highly conserved family of nicotinamide adenine
dinucleotide (NAD+)-dependent deacetylases, deacylases, and
ADP-ribosyltransferases that play various roles in metabolism,
stress response, and longevity (Finkel et al., 2009; Haigis and
Guarente, 2006). In this study, we studied the role of SIRT4,
a mitochondria-localized sirtuin, in cellular metabolic response
to DNA damage and tumorigenesis.
RESULTS
DNA Damage Represses Glutamine Metabolism
To investigate how cells might balance needs for continued
nucleotide synthesis, while also preparing for cell cycle arrest,
we assessed the metabolic response to DNA damage by moni-
toring changes in the cellular consumption of two important
fuels, glucose and glutamine, after DNA damage. Strikingly,
treatment of primary mouse embryonic fibroblasts (MEFs) with
camptothecin (CPT), a topoisomerase 1 inhibitor that causes
double-stranded DNA breaks (DSBs), resulted in a pronounced
reduction in glutamine consumption (Figure 1A). Glutamine
metabolism in mammalian cells is complex and contributes to
a number of metabolic pathways. Glutamine is the primary
nitrogen donor for protein and nucleotide synthesis, which are
essential for cell proliferation (Wise and Thompson, 2010). Addi-
tionally, glutamine provides mitochondrial anaplerosis. Gluta-
mine can be metabolized via glutaminase (GLS) to glutamate
and NH4
+ and further converted to the tricarboxylic acid (TCA)
cycle intermediate a-ketoglutarate via glutamate dehydroge-
nase (GDH) or aminotransferases. This metabolism of glutamine
provides an important entry point of carbon to fuel the TCA cycle
(Jones and Thompson, 2009) and accounts for the majority of
ammonia production in cells (Yang et al., 2009). CPT-induced
reduction of glutamine consumption was accompanied by
a reduction in ammonia secretion from cells (Figure 1B). Notably,
under these conditions, we observed no obvious decrease in
glucose uptake and lactate production (Figures 1C and 1D),
consistent with previous studies showing that intact glucose
utilization through the PPP is important for a normal DNA
damage response (Cosentino et al., 2011). Preservation of
glucose uptake also suggests that repression of glutamine
consumptionmay be a specificmetabolic response to genotoxic
stress and not reflective of a nonspecific metabolic crisis.
To examine the metabolic response to other forms of geno-
toxic stress, we monitored the metabolic response to ultraviolet
(UV) exposure in primary MEFs. Similar to CPT treatment, UV
exposure reduced glutamine uptake without significant changes
in glucose consumption (Figures 1E and 1F). Similarly, two
human cell lines, HepG2 and HEK293T, also demonstrated
marked reductions in glutamine uptake in response to DNA
damaging agents without comparable changes in glucose
uptake (Figures 1G, 1H, S1A, and S1B available online). Taken
together, these results suggest that a variety of primary and
tumor cell lines (murine or human) respond to genotoxic stress
by downregulating glutamine metabolism.
To examine in more detail the changes in cellular glutamine
metabolism after genotoxic stress, we performed a global me-
tabolomic analysis with transformed MEFs before and after
DNA damage. As previously reported, we observed that PPP
intermediates were increased in response to DNA damage(Figures 1I and 1J). Remarkably, we observed a decrease in
measured TCA cycle intermediates after UV exposure (Figures
1I and 1K). Moreover, we found that HepG2 cells showed
a similar metabolomic shift in response to DNA damage (Fig-
ure S1D). We did not observe a clear, coordinated repression
of nucleotides or glutamine-derived amino acids after exposure
to DNA damage (Figure S1C).
To determine whether reduction in TCA cycle metabolites was
the consequence of reduced glutamine metabolism, we per-
formed a time-course tracer study to monitor the incorporation
of [U-13C5]glutamine into TCA cycle intermediates at 0, 2, and
4 hr after UV treatment. We observed that, after UV exposure,
cells reduced contribution of glutamine to TCA cycle intermedi-
ates in a time-dependent manner (Figure 1L). Moreover, the vast
majority of the labeled fumarate and malate contained four
carbon atoms derived from [U-13C5]glutamine (Figure S1F,
M+3 versus M+4), indicating that most glutamine was used in
the nonreductive direction toward succinate, fumarate, and ma-
late production. We were able to observe little contribution of
glutamine flux into nucleotides or glutathione in control or UV-
treated cells at these time points (data not shown), suggesting
that the mitochondrial metabolism of glutamine accounts for
the majority of glutamine consumption in these cells. Taken
together, the metabolic flux analysis demonstrates that DNA
damage results in a reduction of mitochondrial glutamine ana-
plerosis, thus limiting the critical refueling of carbons into the
TCA cycle.
To assess the functional relevance of decreased glutamine
metabolism after DNA damage, we deprived cells of glucose,
thereby shifting cellular dependence to glutamine to maintain
viability (Choo et al., 2010; Dang, 2010). If DNA damage
represses glutamine usage, we reasoned that cells would be
more sensitive to glucose deprivation. Indeed, following 72 hr
of glucose deprivation, cell death in primary MEFs was signifi-
cantly elevated at 10 hr after UV exposure (Figure S1E).
However, cells cultured with glucose remained viable in these
conditions. Thus, these data demonstrate that genotoxic stress
limits glutamine entry into the central mitochondrial metabolism
of the TCA cycle.
SIRT4 Is Induced in Response to Genotoxic Stress
Because sirtuins regulate both cellular metabolism and stress
responses (Finkel et al., 2009; Schwer and Verdin, 2008), we
examined whether sirtuins were involved in the metabolic adap-
tation to DNA damage. We first examined the expression of sir-
tuins in the response to DNA damage. Specifically, we probed
SIRT1, which is involved in stress responses (Haigis and Guar-
ente, 2006), as well as mitochondrial sirtuins (SIRT3–SIRT5),
which have been shown to regulate amino acid metabolism (Hai-
gis et al., 2006; Hallows et al., 2011; Nakagawa et al., 2009).
Remarkably, SIRT4 messenger RNA (mRNA) levels were
induced by nearly 15-fold at 15 hr after CPT treatment and
5-fold after etoposide (ETS), a topoisomerase 2 inhibitor, in
HEK293T cells (Figure 2A). Interestingly, the induction of SIRT4
was significantly higher than the induction of SIRT1 and mito-
chondrial SIRT3 (2-fold), sirtuins known to be induced by
DNA damage and regulate cellular responses to DNA damage
(Sundaresan et al., 2008; Vaziri et al., 2001; Wang et al., 2006).
Moreover, overall mitochondrial mass was increased by onlyCancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc. 451
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Figure 1. Glutamine Metabolism Is Repressed by Genotoxic Stress
(A and B) Glutamine uptake (A) and ammonia production (B) in primary MEFs incubated with or without 14 mM CPT for 12 hr (n = 8–9).
(C and D) Glucose uptake (C) and lactate production (D) in primary MEFs treated as indicated in Figure 1A (n = 8–9).
(E and F) Glutamine (E) and glucose (F) uptake in primary MEFs measured at 6 hr after 30 J/m2 UV exposure (n = 3).
(G and H) Glutamine (G) and glucose (H) uptake in HepG2 cells treated with or without 14 mM CPT for 12 hr or at 6 hr after 30 J/m2 UV exposure (n = 3–6).
(I) Schematic illustrating the metabolites that are increased (red) or decreased (blue) in transformed MEFs at 4 hr after 20 J/m2 UV exposure (n = 4; p < 0.05).
Metabolites in parentheses were not measured.
(J and K) Heat map comparing relative levels of intermediates in transformed MEFs measured at 4 hr after 20 J/m2 UV exposure when compared with an
untreated control (n = 4 samples of each condition). Blue and red indicates down- or upregulation, respectively.
(legend continued on next page)
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Figure 2. SIRT4 Is Induced by DNA Damage
Stimuli
(A) Relative mRNA expression levels of indicated
sirtuins in HEK293T cells treated with 14 mM CPT
or 25 mM ETS for 15 hr were measured by quan-
titative RT-PCR (qRT-PCR) (n = 4). b-actin was
used as an endogenous control for qRT-PCR.
(B) Relative Sirt4 mRNA levels in primary MEFs at
12 hr after treatment with CPT (14 mM), ETS
(25 mM), IR (5 Gy), or UV (30 J/m2) were measured
by qRT-PCR (n = 3–4). b-actin was used as an
endogenous control for qRT-PCR.
(C)SIRT4protein inwholecell lysates fromHEK293T
cells treated with CPT (14 mM) or ETS (25 mM) for
15 hr was detected by immunoblotting with anti-
human SIRT4. b-actin serves as a loading control.
(D) SIRT4 protein in transformed WT and SIRT4
KO MEFs treated CPT (14 mM) for the indicated
times. b-actin serves as a loading control.
Data are means ± SEM. *p < 0.05, **p < 0.005, and
***p < 0.0001.
See also Figure S2.
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SIRT4 Functions as a Tumor Suppressor10% in comparisonwith control cells (Figure S2A), indicating that
the induction of SIRT4 is not an indirect consequence of mito-
chondrial biogenesis. These data hint that SIRT4 may have an
important, previously undetermined role in the DDR.
To test the induction of SIRT4 in the general genotoxic stress
response, we treated cells with other types of DNA damage,
including UV and gamma-irradiation (IR). SIRT4 mRNA levels
were also increased by these genotoxic agents (Figures S2B
and S2C), and low doses of CPT and UV treatment also induced
SIRT4 expression (Figures S2D and S2E). We observed similar
results with MEFs (Figures 2B, 2D, and S2F) and HepG2 cells
(Figure S2G). DNA-damaging agents elevated SIRT4 in p53-
inactive HEK293T cells (Figures 2A and 2C) and in p53 null
PC3 human prostate cancer cells (Figure S2H), suggesting that
SIRT4 can be induced in a p53-independent manner.
To examine whether the induction of SIRT4 occurred as
a result of cell cycle arrest, we measured SIRT4 levels after the
treatment of nocodazole, which inhibits microtubule polymeriza-
tion to block mitosis. While treatment with nocodazole
completely inhibited cell proliferation (data not shown), SIRT4
expression was not elevated (Figure S2I). In addition, we
analyzed SIRT4 expression in distinct stages of the cell cycle
in HepG2 cells synchronized with thymidine block (Figure S2J,
left). SIRT4 mRNA levels were measured at different times after
release and were not elevated during G1 or G2/M phases (Fig-
ure S2J, right), suggesting that SIRT4 is not induced as a general
consequence of cell cycle arrest. Next, we re-examined the
localization of SIRT4 after DNA damage. SIRT4 localizes to the
mitochondria of human andmouse cells under basal, unstressed
conditions (Ahuja et al., 2007; Haigis et al., 2006). Following CPT
treatment, SIRT4 colocalized with MitoTracker, a mitochondrial-
selective marker, indicating that SIRT4 retains its mitochondrial
localization after exposure to DNA damage (Figure S2K). Taken(L) Heat map of 13C-glutamine contributed to labeled TCA cycle intermediates at
changes are relative incorporation compared to each non-UV treated control aft
Data are means ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0001.
See also Figure S1.together, our findings demonstrate that SIRT4 is induced by
multiple forms of DNA damage in numerous cell types, perhaps
to coordinate the mitochondrial response to genotoxic stress.
SIRT4 Represses Glutamine Anaplerosis
We observed that glutamine anaplerosis is repressed by geno-
toxic stress (Figure 1) and SIRT4 is induced by DNA damage
(Figure 2). Additionally, previous studies reported that SIRT4
represses glutamine anaplerosis (Haigis et al., 2006). We next
tested whether SIRT4 directly regulates cellular glutamine
metabolism and contribution of glutamine to the TCA cycle.
Like DNA damage, SIRT4 overexpression (SIRT4-OE) in
HepG2, HeLa, or HEK293T cells resulted in the repression of
glutamine consumption (Figures 3A and S3A–S3C). Conversely,
SIRT4 knockout (KO) MEFs consumed more glutamine than did
wild-type (WT) cells (Figure 3B).
Mitochondrial glutamine catabolism refuels the TCA cycle and
is essential for viability in the absence of glucose (Choo et al.,
2010; Yang et al., 2009). Thus, we examined the effect of
SIRT4 on cell survival during glucose deprivation. Overexpres-
sion of SIRT4 in HEK293T or HeLa cells increased cell death in
glucose-free media compared to control cells (Figure 3C; Fig-
ure S3D). Importantly, this cell death was completely rescued
by the addition of pyruvate or cell permeable dimethyl a-ketoglu-
tarate (DM-KG), demonstrating that SIRT4 overexpression
reduced the ability of cells to utilize glutamine for mitochondrial
energy production. Moreover, cell death was equally maximized
in the absence of glucose and presence of the mitochondrial
ATPase inhibitor oligomycin (Figure 3C). These findings are in
line with the model that SIRT4 induction with DNA damage limits
glutamine metabolism and utilization by the TCA cycle.
We next utilized a metabolomic approach to interrogate
glutamine usage in the absence of SIRT4. SIRT4 KO MEFs0, 2, and 4 hr after 20 J/m2 UV exposure (n = 4 samples of each condition). All
er pulse of 13C-glutamine.
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Figure 3. SIRT4 Represses Mitochondrial Glutamine Metabolism in Response to DNA Damage
(A and B) Glutamine uptake in HepG2 cells stably expressing empty vector (Vector) or SIRT4 (SIRT4-OE) (A) or in immortalizedWT and SIRT4 KOMEFs (B) (n = 3).
(C) HEK293T Vector or SIRT4-OE cells deprived of glucose were given DM-KG (7 mM), pyruvate (1 mM), and/or oligomycin (5 mg/ml). Cell viability was measured
via PI exclusion assay (n = 3).
(D) Relative abundance of 13C-labeled TCA cycle intermediates (M+5 for a-ketoglutarate or M+4 for others) to the unlabeled from transformedWT and SIRT4 KO
MEFs at the indicated times after pulse of 13C-glutamine (n = 4 samples of each condition).
(E) Glutamine uptake in immortalized WT and SIRT4 KO MEFs treated with DMSO or BPTES (10 mM) (n = 3–4).
(F) GLS1 protein levels in HEK293T cells expressing GLS1-specific (shGLS#1 and shGLS#2) or control (shGFP) shRNAs. b-actin serves as a loading control.
(G) Glutamine uptake in control (shGFP) or GLS-knockdown (shGLS#1 and shGLS#2) cells after transfection with empty vector (Vector) and SIRT4 (SIRT4-OE)
(n = 3).
(H) Relative glutamine uptake to each control in transformed WT and SIRT4 KO MEFs measured at the indicated times after 20 J/m2 UV exposure (n = 3).
(I) Glutamine uptake in DMSO or BPTES (10 mM)-treated, immortalized MEFs after 20 J/m2 UV exposure (n = 3).
(J) Heat map comparing relative levels of TCA cycle intermediates in transformed WT and SIRT4 KO MEFs at 4 hr after 20 J/m2 UV exposure (n = 4).
Data are means ± SEM. n.s., not significant. *p < 0.05, **p < 0.005, and ***p < 0.0001.
See also Figure S3.
Cancer Cell
SIRT4 Functions as a Tumor Suppressor
454 Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc.
Cancer Cell
SIRT4 Functions as a Tumor Suppressordemonstrated elevated levels of TCA cycle intermediates (Fig-
ure 3J, WT versus KO), whereas intermediates of glycolysis
were comparable with WT cells (data not shown). Nucleotides
and other metabolites downstream of glutamine metabolism
were not coordinately regulated by SIRT4 loss (Figure S3E;
data not shown). Next, we analyzed glutamine flux in WT and
SIRT4 KO MEFs in medium containing [U-13C5]glutamine for 2
or 4 hr and measured isotopic enrichment of TCA cycle interme-
diates. Loss of SIRT4 promoted a higher rate of incorporation of
13C-labeled metabolites derived from [U-13C5]glutamine in all
TCA cycle intermediates measured (Figure 3D). These data
provide direct evidence that SIRT4 loss drives increased entry
of glutamine-derived carbon into the TCA cycle.
Next, we examined the mechanisms involved in this repres-
sion of glutamine anaplerosis. GLS is the first required enzyme
for mitochondrial glutamine metabolism (Curthoys and Watford,
1995), and its inhibition limits glutamine flux into the TCA cycle
(Wang et al., 2010; Le et al., 2012; Yuneva et al., 2012). Treat-
ment with bis-2-(5-phenylacetoamido-1,2,4-thiadiazol-2-yl)ethyl
sulfide (BPTES) (Robinson et al., 2007), an inhibitor of GLS1,
repressed glutamine uptake and completely rescued the
increased glutamine consumption of SIRT4 KO cells (Figure 3E).
Moreover, SIRT4 overexpression no longer inhibited glutamine
uptake when GLS1 was reduced by using short hairpin RNAs
(shRNAs) (Figures 3F and 3G), demonstrating that SIRT4 regu-
lates mitochondrial glutamine metabolism. SIRT4 is a negative
regulator of GDH activity (Haigis et al., 2006), and SIRT4 KO
MEFs exhibited increased GDH activity in comparison with WT
MEFs (Figure S3F). To test whether SIRT4 regulates mitochon-
drial glutamine metabolism via inhibiting GDH activity, we
measured glutamine uptake in WT and SIRT4 KO cells in the
presence of epigallocatechin gallate (EGCG), a GDH inhibitor
(Choo et al., 2010; Li et al., 2006). The treatment of EGCG
partially rescued the increased glutamine uptake of KO cells (Fig-
ure S3G), suggesting that GDH contributes to the role of SIRT4
in glutamine metabolism.
SIRT4 Represses Mitochondrial Glutamine Metabolism
after DNA Damage
The induction of SIRT4 after DNA damage and regulation of
glutamine metabolism by SIRT4 led us to speculate that SIRT4
may repress glutamine anaplerosis in response to DNA damage.
Thus, we measured cellular glutamine consumption after UV
exposure with transformed and nontransformed WT and SIRT4
KO MEFs. As expected, UV treatment suppressed glutamine
uptake in WT cells (Figures 3H and S3H). Strikingly, we found
that KO cells were unable to repress glutamine uptake in
response to DNA damage (Figures 3H and S3H). We tested the
involvement of glutamine anaplerosis by treating cells with
chemical inhibitors of GLS1. Intriguingly, UV treatment could
not further repress glutamine uptake in the presence of BPTES
(Figure 3I), indicating that DNA damage inhibits mitochondrial
glutamine metabolism. In addition, we observed similar results
with the compound 968, a small molecule inhibitor of GLS1 (Fig-
ure S3I; Wang et al., 2010).
To probe further whether SIRT4 limits glutamine utilization to
repress the TCA cycle after DNA damage, we performed metab-
olomic analysis with WT and SIRT4 KOMEFs with or without UV
exposure. The levels of several TCA cycle intermediates re-mained elevated in KO cells compared to WT cells after UV
exposure (Figure 3J), corroborating the idea that SIRT4 is
required for the proper repression of mitochondrial glutamine
metabolism in response to DNA damage.
SIRT4 Regulates Cell Cycle Progression and Genomic
Fidelity in Response to DNA Damage
DNA damage initiates cell cycle arrest, which is crucial for main-
tenance of genomic integrity and ultimately for the prevention of
cancer (Ciccia and Elledge, 2010). Glutamine is an essential
metabolite for proliferation (Gaglio et al., 2009; Jones and
Thompson, 2009; Wise and Thompson, 2010) and required for
transition from G1 to S phase (Colombo et al., 2011). Because
our studies demonstrate that SIRT4 is induced by DNA damage
to repress the utilization of glutamine, we interrogated the role of
SIRT4 in cell cycle progression after DNA damage. To induce
DNA damage independently of the rate of proliferation, we
treated WT and SIRT4 KO MEFs with UV radiation and then
pulsed with bromodeoxyuridine (BrdU) for 30 min, followed by
staining with anti-BrdU fluorescein isothiocyanate (FITC) and
7-aminoactinomycin D. As expected, the population of the
BrdU-labeled [BrdU+ (S phase), (a) + (b)] cells was decreased
in WT cells in a time-dependent manner (Figures 4A and S4A).
However, this inhibition of BrdU incorporation was significantly
delayed in KO MEFs, and this difference was most noticeable
in cells in early S phase (Figure 4A, (a)). These cells were in G1
phase at the time of UV treatment and entered S phase during
pulsing with BrdU. We observed similar results with IR treatment
(Figure S4B). At 6 hr after IR treatment, G1 phase cells were
nearly absent in KO cells but still present in WT cells (Figure S4B,
red circle).
To probe the connection between glutamine metabolism and
cell cycle arrest after DNA damage, we tested whether the inhi-
bition of DNA synthesis upon DNA damage would be affected by
the addition of a downstream metabolite of glutamine. We
treated cells with dimethyl-glutamate (DMG), a cell-permeable
glutamate donor (Maechler and Wollheim, 1999), and measured
the level of BrdU+ cells after UV treatment. To our surprise, DMG
treatment promoted BrdU incorporation in response to DNA
damage, as more cells entered early S phase by the addition
of DMG (Figures 4B and S4C, PBS versus DMG). DMG treatment
did not augment normal cell cycle proliferation (Figure S4D).
Although the treatment of DMG caused a mild increase in the
proportion of BrdU+ cells in the KO cells, the fraction of BrdU+
cells in WT cells increased robustly upon DMG treatment
compared to PBS treatment (Figure S4E). These data suggest
that reduced glutamine metabolism may limit proliferation,
contributing to a metabolic checkpoint in response to genotoxic
stress. Bypassing this checkpoint by adding soluble metabolites
downstream of glutamine can partially promote cell cycle
progression, even in the presence of DNA-damaging conditions.
Defects in the DDRmay lead to accumulation of DNA damage
and also may promote cell death. To assess whether SIRT4
affects genomic integrity in response to genotoxic stress, WT
and SIRT4 KO cells were irradiated and then the number of
gH2AX foci, known to localize at DSBs (Rogakou et al., 1998),
was counted. The clearance of gH2AX foci was significantly
impaired in KO cells (Figure 4C), while SIRT4 overexpression
accelerated the clearance of foci (Figure 4D). Moreover, SIRT4Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc. 455
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Figure 4. SIRT4 Is Involved in Cellular DNA Damage Responses
(A) The measurement of BrdU+ cells and total DNA content in transformed WT and SIRT4 KO MEFs at the indicated times after 20 J/m2 UV exposure (n = 3).
(B) The BrdU+ cell and total DNA content in transformed WT MEFs incubated with PBS or DMG (10 mM) after UV exposure (n = 3).
(C and D) The number of g-H2AX foci in immortalizedWT and SIRT4 KOMEFs (C) or Vector and SIRT4-OE HeLa cells (D) was counted at the indicated times after
IR treatment.
(E and F) Survival of immortalized WT and SIRT4 KO MEFs (E) or Vector and SIRT4-OE HepG2 cells (F) treated with or without CPT (14 mM) or UV (30 J/m2)
(n = 3–4). Cell viability was measured via PI exclusion assay.
(G) Survival of HepG2 cells expressing control (shGFP) or GLS1-specific (shGLS#1 and shGLS#2) shRNAs were treated with DMSO or CPT (14 mM) for 24 hr
(n = 3). Cell viability was measured via PI exclusion assay.
(H and I) The percentage of chromosome number (H) and representative images of chromosome spread (I) of WT and SIRT4 KOMEFs at passage 2. Numbers of
spreads counted were 64, 61, 142, and 104 for WT-1, WT-2, KO-1, and KO-2, respectively. Scale bar, 10 mm.
(J) Transformed WT and SIRT4 KO MEFs were treated with or without 20 J/m2 UV, and the percentage of cells containing greater than 4n is analyzed by flow
cytometry (n = 3).
(K) Immunofluorescent staining of transformedWT and SIRT4 KOMEFs using nuclear (DAPI) and DSBs (g-H2AX) markers (left). Scale bar, 10 mm. The percentage
of nuclei with the indicated number of gH2AX foci (right). WT MEFs (n = 119); KO MEFs (n = 71).
Data are means ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0001.
See also Figure S4.
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SIRT4 Functions as a Tumor SuppressorKO cells showed significantly elevated levels of cell death
compared to WT cells (Figure 4E), while SIRT4 overexpression
was protective (Figure 4F). We next examined survival of control
and GLS1 knockdown cells against DNA damage and discov-456 Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc.ered that inhibition of mitochondrial glutamine metabolism can
mirror the protective role of SIRT4 overexpression (Figure 4G),
demonstrating a link between mitochondrial glutamine metabo-
lism and the DDR.
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Figure 5. SIRT4 Has Tumor-Suppressive Function
(A and B) Growth curves of WT and SIRT4 KOMEFs (n = 3) cultured in standard media (A) or media supplemented with BPTES (10 mM) (B). Data are means ± SD.
(C and D) Growth curves of Vector and SIRT4-OE HeLa cells (n = 3) cultured in standard media (C) or media supplemented with BPTES (10 mM) (D). Data are
means ± SD.
(E) Focus formation assays with transformedWT and SIRT4 KOMEFs (left). Cells were cultured with normal medium or medium without glucose or glutamine for
10 days and stained with crystal violet. The number of colonies was counted (right) (n = 3 samples of each condition). n.d., not determined.
(F) Focus formation assays with transformed KOMEFs reconstituted with SIRT4 or a catalytic mutant of SIRT4 (n = 3). Cells were cultured for 8 days and stained
with crystal violet.
(G) Contact inhibited cell growth of transformed WT and SIRT4 KO MEFs cultured in the presence of DMSO or BPTES (10 mM) for 14 days (left). The number of
colonies was counted (right). Data are means ± SEM. n.s., not significant. *p < 0.05 and **p < 0.005.
See also Figure S5.
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SIRT4 Functions as a Tumor SuppressorGiven the role for SIRT4 in regulating themetabolic checkpoint
in response to DNA damage, we analyzed whether SIRT4 loss
influenced chromosome stability. Chromosome spreads from
two pairs of WT and SIRT4 KO primary MEFs revealed that KO
cells possessed more aneuploidy (Figures 4H and 4I). Further-
more, more polyploidy cells were found in transformed KO cells
compared to WT cells, and this phenotype became more severe
after UV treatment (Figure 4J). Aberrant activation of the retino-
blastoma (Rb)-E2F pathway by oncogenes leads to the replica-
tion-induced DSBs and formation of gH2AX foci (Bester et al.,
2011). Hence, we analyzed the formation of gH2AX foci of WT
and SIRT4 KO MEFs transformed with Ras and E1A, known to
inactivate Rb (Harbour and Dean, 2000) and observed elevated
gH2AX foci in KO cells (Figure 4K). Taken together, findings
from multiple approaches demonstrate that SIRT4 is a critical
regulator of genome fidelity.SIRT4 Represses Tumor Proliferation
Genomic instability is one hallmark of tumorigenicity. Another
feature of tumor cells is rapid cell proliferation, fueled in some
cases by elevated glutamine utilization (Jones and Thompson,
2009; Wise and Thompson, 2010). Thus, we tested the idea
that increased glutamine metabolism in SIRT4 KO MEFs may
support proliferation. Indeed, KO cells significantly grew faster
than did WT cells (Figure 5A). To test whether enhanced gluta-
mine metabolism contributed to the proliferative phenotype of
KO cells, we cultured cells with GLS1 inhibitors and measured
proliferation. Remarkably, BPTES and 968 completely abro-
gated the increased proliferation of KO cells (Figures 5B and
S5A). To probe the contribution of GDH, we measured prolifera-
tion in presence of EGCG and found it likewise abrogated the
proliferative phenotype of KO cells (Figure S5B). In contrast,
overexpression of SIRT4 in HeLa cells, which use glutamine asCancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc. 457
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SIRT4 Functions as a Tumor Suppressora major energy source, significantly inhibited their growth (Fig-
ure 5C). Importantly, control and SIRT4-overexpressing cells
proliferated at similar rates when cultured in media containing
BPTES or 968 (Figures 5D and S5C), highlighting the role of
SIRT4 in this pathway.
Defects in the proper regulation of DNA damage responses
can result in the accumulation of DNA lesions, leading to cancer
development (Lapenna and Giordano, 2009). Moreover, gluta-
mine metabolism is critical for oncogenic transformation and
cancer cell proliferation (DeBerardinis et al., 2007; Wang
et al., 2010; Weinberg et al., 2010). Thus, we reasoned that
SIRT4 would have the potential to suppress tumorigenesis by
repressing glutamine metabolism and/or genomic instability.
Thus, we assessed tumorigenic properties of transformed
SIRT4 KO MEFs. KO MEFs formed more colonies than WT
MEFs in colony formation assays (Figure 5E). Neither KO cells
nor WT cells were able to form colonies on glutamine-deficient
media. In contrast, SIRT4 KO MEFs were able to form a few
colonies under glucose-deprived conditions, while WT cells
were not, demonstrating that SIRT4 loss facilitates glutamine
utilization to support colony formation. We found that reconsti-
tution of KO cells with SIRT4 can reverse the phenotype,
whereas reconstitution with a catalytic mutant of SIRT4 cannot
(Figures 5F and S5D).
We next probed the contribution of glutamine anaplerosis in
the transformative properties of SIRT4 KO cells. Cancer cells
exhibit loss of contact inhibition of proliferation, resulting
in uncontrolled cell proliferation. WT and SIRT4 KO MEFs were
transformed in media supplemented with DMSO or BPTES, and
colony-forming activities were determined. KO cells possessed
increased colony-forming activity compared to WT cells (Fig-
ure 5G). This difference was inhibited by GLS or GDH inhibitors
(Figures 5G and S5E), indicating that glutamine anaplerosis
contributes to the tumorigenic phenotype of SIRT4 null cells.
SIRT4 Represses Tumor Formation In Vivo
To investigate SIRT4 function in human cancers, we examined
changes in SIRT4 expression. SIRT4 mRNA level was reduced
in several human cancers, such as small-cell lung carcinoma
(Garber et al., 2001), gastric cancer (Wang et al., 2012), bladder
carcinoma (Blaveri et al., 2005), breast cancer (The Cancer
Genome Atlas; http://tcga-data.nci.nih.gov/tcga/), and leukemia
(Choi et al., 2007; Figure 6A). Of note, lower SIRT4 expression
was associated with shorter time to death in lung tumor patients
(Shedden et al., 2008; Figure 6B). Overall, the expression data
is consistent with the model that SIRT4 may play a tumor-
suppressive role in human cancers.
To extend the cellular findings to in vivo models, we used
multiple approaches. First, we performed allograft tumor forma-
tion assays in nude mice using transformed MEFs. Accordant
with cellular models, loss of SIRT4 promoted larger tumor
volume and weight compared to WT tumors in the recipient
mice (Figure 6C). We next examined spontaneous tumor forma-
tion in two independent SIRT4 KO mouse strains, including in
another strain of whole-body SIRT4 KO mice, generated by
deleting exons 3 and 4 (Figure S6A). Like the previously reported
SIRT4 KO model (Haigis et al., 2006), these SIRT4 KO mice
demonstrated normal development and size. Strikingly, SIRT4
loss increased spontaneous tumor incidence throughout life458 Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc.(Figure 6D). Approximately 63% (22/35) of the Sirt4 null animals
developed several types of tumors, most frequently lung tumors
at 18–26 months of age, while 20% (5/25) of agedWT littermates
developed lung tumors (Figures 6E and S6B). Lung tumors from
SIRT4 KO mice were categorized according to tumor types,
revealing 41% (7/17) adenomas, and 59% (10/17) carcinomas,
including bronchioloalveolar carcinoma and adenocarcinomas
(Figure 6F). To further characterize these tumors, we performed
immunohistochemistry to detect thyroid transcription factor-1
(TTF1), a transcription factor expressed specifically in epithelial
cells of the thyroid and lung, providing a clinical marker in the
diagnosis of tumors of lung origin (Kendall et al., 2007; Weir
et al., 2007). Lung tumors from SIRT4 KO mice were positive
for TTF1 (Figure 6G). Moreover, we found that 60% (9/15) of
female Sirt4 null animals also developed cystic endometrial
hyperplasia, while only 15% (2/13) WT mice exhibited mild
endometrial hyperplasia (Figure 6E).
The previously reported strain of SIRT4 KO mice (Haigis et al.,
2006) demonstrated the same phenotype; these SIRT4 KO
animals developed lung tumors (45.5%) more frequently than
WT mice (8.3%) between 18 and 22 months of age (Figure S6C).
Thus, two independently derived strains of SIRT4 KO mice
possessed increased spontaneous lung tumor incidence.
SIRT4 Regulates Glutamine Metabolism in Lung Tissue
To test further the biological relevance of this pathway in lung, we
examined whether SIRT4 is induced in vivo after exposure to
DNA-damaging IR treatment. Remarkably, Sirt4 was signifi-
cantly induced in lung tissue after IR exposure (Figure 7A). We
next examined whether IR repressed glutamine metabolism
in vivo, as observed in cell culture by examining GDH activity
in lung tissue from WT and SIRT4 KO mice with or without IR
exposure. GDH activity was elevated in lung tissue extracts
from SIRT4 KO mice compared with WT lung tissue (Figure 7B).
Importantly, GDH activity was significantly decreased in lung
tissue fromWTmice after IR exposure, whereas not in lung tissue
from KO mice (Figure 7C). Thus, these findings recapitulate our
cellular studies and are in line with the model that SIRT4 induc-
tion with DNA damage limits mitochondrial glutamine metabo-
lism and utilization.
To assess whether the functions of SIRT4 can be reproduced
in these lung tumors, cells derived from SIRT4 KO lung tumors
were reconstituted with wild-type SIRT4 (Figure S7A). As ex-
pected, SIRT4 reconstitution reduced glutamine uptake but not
glucose uptake (Figures 7D and 7E) and repressed proliferation
(Figure S7B) of lung tumor cells. Finally, we tested whether
SIRT4 repressed genomic instability in these tumor cells after
DNA damage. When we examined the chromosome abnormali-
ties after irradiation, the reconstituted tumor cells with SIRT4
exhibit decreased genomic instability (Figure 7F). Taken
together, these results provide critical evidence that SIRT4 regu-
lates both glutamine metabolism and genomic instability in
tumor cells and that loss of this critical regulatory node contrib-
utes to cancer susceptibility.
DISCUSSION
Here, we report that SIRT4 has an important role in cellular meta-
bolic response to DNA damage by regulating mitochondrial
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Figure 6. SIRT4 Is a Mitochondrial Tumor Suppressor
(A) SIRT4 mRNA levels were determined using the Oncomine microarray database (http://www.oncomine.org) in normal versus lung, gastric, bladder, breast
cancer, and leukemia. The boxes represent the interquartile range; whiskers represent the 10th–90th percentile range; bars represent the median. LAD, lung
adenocarcinoma; SCLC, small-cell lung carcinoma; IBUC, infiltrating bladder urothelial carcinoma; IDBC, invasive ductal breast carcinoma; ILBC, invasive
lobular breast carcinoma.
(B) Kaplan-Meier curve comparing time to survival between lung adenocarcinomas with the lowest (<25th percentile) versus highest (>25th percentile) SIRT4
expression was determined using the Oncomine database. p = 0.0354, log rank test.
(C) Representative image of tumors resulting from allograft with transformed WT and SIRT4 KO MEFs. Tumor volume and weight were measured (n = 8 tumors/
genotypes). The boxes represent the interquartile range; whiskers represent the 10th–90th percentile range; bars represent the median.
(D and E) Tumor-free curve (D) and analysis of tumor types (E) in WT and SIRT4 KO mice. p = 0.0035, log rank test.
(F) Histological sections of representative lung tumors from SIRT4 KO mice with H&E staining. Scale bar, 20 mm.
(G) Immunofluorescent staining of a representative lung adenocarcinoma from SIRT4 KO mice using nuclear (DAPI) and lung (TTF1) markers. Scale bar, 20 mm.
Data are means ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0001.
See also Figure S6.
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SIRT4 Functions as a Tumor Suppressorglutamine metabolism with important implication for the DDR
and tumorigenesis. First, we discovered that DNA damage
represses cellular glutamine metabolism (Figure 1). Second,
we found that SIRT4 is induced by genotoxic stress (Figure 2)
and is required for the repression of mitochondrial glutamine
metabolism (Figure 3). This metabolic response contributes to
the control of cell cycle progression and the maintenance of
genomic integrity in response to DNA damage (Figure 4). Loss
of SIRT4 increased glutamine-dependent tumor cell proliferation
and tumorigenesis (Figure 5). In mice, SIRT4 loss resulted in
spontaneous tumor development (Figure 6). We demonstrate
that SIRT4 is induced in normal lung tissue in response to DNA
damage, where it represses GDH activity. Finally, the glutamine
metabolism-genomic fidelity axis is recapitulated in lung tumor
cells derived from SIRT4 KO mice via SIRT4 reconstitution (Fig-
ure 7). Our studies therefore uncover SIRT4 as an importantregulator of cellular metabolic response to DNA damage that
coordinates repression of glutamine metabolism, genomic
stability, and tumor suppression.
The DDR is a highly orchestrated and well-studied signaling
response that detects and repairs DNA damage. Upon sensing
DNA damage, the ATM/ATR protein kinases are activated to
phosphorylate target proteins, leading to cell cycle arrest, DNA
repair, transcriptional regulation, and initiation of apoptosis (Cic-
cia and Elledge, 2010; Su, 2006). Dysregulation of this pathway is
frequently observed in many tumors. Emerging evidence has
suggested that cell metabolism also plays key roles downstream
of the DDR-induced pathways. For example, ATM has been re-
ported to repress the rapamycin-sensitive mammalian target of
rapamycin (mTORC1) pathway by activating the serine/threo-
nine kinase LKB1/AMP-activated protein kinase (AMPK) meta-
bolic pathway (Alexander et al., 2010). Several studies alsoCancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc. 459
WT KO
20
22
24
26
28
G
D
H 
ac
tiv
ity
 (n
m
ol
/m
in
/g
)
Control IR
18
20
22
24
26
G
D
H 
ac
tiv
ity
 (n
m
ol
/m
in
/g
)
WT
Control IR
22
24
26
28
KO
Control 3h 6h 12h
0.0
0.5
1.0
1.5
IR
Re
la
tiv
e
Si
rt4
 le
ve
ls
A
SIRT4
Genotoxic stress
Mitochondrial
Glutamine
metabolism
Metabolic pause
arrest/repair
Genomic stability
Tumor
B C
D
Vector SIRT4
0.0
0.5
1.0
R
el
at
ive
 G
lu
ta
m
in
e 
up
ta
ke
Vector SIRT4
0.0
0.5
1.0
R
el
at
ive
 G
lu
co
se
 u
pt
ak
e
Abnormality Vector (n = 36) SIRT4 (n = 35)
gross abnormalities 25 (69.4%) 22 (62.9%)
premature segregation 5 (13.9%) 2 (5.7%)
multiple quadriradial chromosomes 4 (11.1%) 1 (2.9%)
1 quadriradial chromosomes 0 (0%) 1 (2.9%)
E
F
G
* *
**
***
*
n.s.
Figure 7. SIRT4 Inhibits Mitochondrial Glutamine Metabolism In Vivo
(A) Relative Sirt4 mRNA levels in lung tissues for the indicated times after whole-body IR (10 Gy) were determined by qRT-PCR (n = 3). b-actin was used as an
endogenous control for qRT-PCR.
(B) GDH activity in lung tissue extracts from WT and SIRT4 KO mice (n = 5 animals/genotype).
(C) GDH activity in lung tissue extracts from WT (left) and SIRT4 KO (right) mice at 12 hr after whole body IR (10 Gy) (n = 5–6 mice of each condition).
(D and E) Glutamine (D) and glucose (E) uptake in SIRT4 KO lung tumor cells reconstituted with SIRT4 (n = 3).
(F) Chromosomal abnormalities were examined in SIRT4 KO lung tumor cells reconstituted with SIRT4 after IR (5 Gy) treatment.
(G) A proposed model illustrating the regulation of metabolic response to DNA damage by SIRT4.
Data are means ± SEM. n.s., not significant. *p < 0.05 and **p < 0.005.
See also Figure S7.
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SIRT4 Functions as a Tumor Suppressorindicate that AMPK is activated downstream of p53 via p53
target genes, sestrin 1 and sestrin 2 (Shackelford and Shaw,
2009). Moreover, damaged cells upregulate the PPP to facilitate
DNA repair by generating precursors for nucleotide biosynthesis
(Cosentino et al., 2011). The role of SIRT4 in the metabolic
response to genotoxic stress synergizes with changes in cellular
signaling pathways. SIRT4 contributes to this stress response by
repressing glutamine entry into TCA cycle.
How does diminished glutamine metabolism regulate cellular
responses to genotoxic stress? Proliferating cells use precursors
derived from TCA cycle intermediates to synthesize NAD phos-
phate (NADPH), lipids, proteins, and nucleic acids (DeBerardinis
et al., 2007;Wise and Thompson, 2010). For example, mitochon-
drial citrate is exported to the cytosol and is used for lipid
synthesis and protein acetylation. However, continuous export
of TCA cycle intermediates would result in the loss of mitochon-
drial integrity by stalling the TCA cycle, limiting anabolic path-
ways, and decreasing substrates for cellular respiration. Thus,
refilling the mitochondrial carbon pool by glutamine is essential
for the maintenance of mitochondrial integrity and its biosyn-460 Cancer Cell 23, 450–463, April 15, 2013 ª2013 Elsevier Inc.thetic roles, as has been previously demonstrated (DeBerardinis
et al., 2007).We find that this pathway is repressed in response to
cellular stress and additionally demonstrate that SIRT4 regulates
glutamine anaplerosis.
Although our current work highlights the regulation of gluta-
mine anaplerosis by SIRT4, other glutamine metabolism path-
ways may also be important for the DDR and tumorigenesis.
For example, glutamine contributes to de novo synthesis of
glutathione (GSH), an intracellular antioxidant that plays a critical
role in cellular defense against oxidative stress (Lu, 2009). Our
studies did not find a significant difference in the levels of GSH
and GSH dimers and no measurable flux of glutamine into
GSH under these conditions and at short time points after
damage (data not shown). Glutamine metabolism also contrib-
utes to lipid synthesis, nucleotide synthesis, and NADPH levels.
Sirtuins have several targets and synergically regulate the same
pathway. For example, SIRT3 has been shown to bind and regu-
late multiple enzymes in mitochondrial fatty-acid oxidation
(Hallows et al., 2011; Hirschey et al., 2010). Thus, it will be inter-
esting for future studies to examine systematically whether
Cancer Cell
SIRT4 Functions as a Tumor SuppressorSIRT4 regulates mitochondrial glutamine metabolism and other
branches of glutamine metabolism via other targets.
This study identifies an important role for SIRT4 in suppressing
tumor growth using a combination of human data and cellular
and mouse experiments. In humans, SIRT4 mutations have
been identified in colon, lung, and uterine carcinomas (http://
www.cbioportal.org). Moreover, SIRT4 expression is decreased
in human tumors and correlates with prognosis in lung cancer
patients. Our cellular and animal studies also reveal that SIRT4
loss increases tumorigenesis, importantly in a glutamine-depen-
dent manner. These findings also share parallels with the role of
SIRT3, another mitochondrial sirtuin, in tumorigenesis. Like
SIRT3, the tumors in SIRT4 KO mice arise in an age-dependent
manner—after 1 year. Thus, as with SIRT3, SIRT4 loss on its own
may not be the initiating event in tumorigenesis, but its loss
appears to create a tumor-permissive environment to promote
both increased genomic instability and anabolic growth, sup-
porting tumor cell survival and proliferation.
Several other sirtuins have been shown to play critical roles in
genome maintenance and tumorigenesis. For example, SIRT1-
and SIRT6-deficient cells showed an impaired DSB repair and
SIRT2, SIRT3, and SIRT6 KOmice exhibit spontaneous genomic
instability (Kim et al., 2010; Mao et al., 2011; Mostoslavsky et al.,
2006; Oberdoerffer et al., 2008; Wang and Tong, 2009). As
sirtuins are important modulators of cell metabolism (Haigis
and Guarente, 2006; Houtkooper et al., 2012), it will be inter-
esting to examine whether these sirtuins coordinately regulate
genomic fidelity and tumorigenesis, in part via modulating fuel
switching.
In sum, our studies reveal an important role for the mitochon-
drial sirtuin, SIRT4, in cancer biology and connect two hallmarks
of tumor cells: genomic instability and dysregulation of
glutamine metabolism. Given the importance of metabolism in
cellular proliferation and tumorigenesis, these findings hold
profound implications for understanding the normal metabolic
response to stress as well as for the development of cancer
therapy.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal studieswere performed according to protocols approved by the Institu-
tional Animal Care and Use Committee, the Standing Committee on Animals at
Harvard. Age-matched SIRT4 WT and KOmice were sacrificed and subjected
to pathological examination. For allograft studies, 106 transformed SIRT4 WT
or KO MEFs in Matrigel (BD Bioscience) for a total volume of 100 ml were in-
jected subcutaneously in right and left flanks of 8-week-old male nude mice
(Charles River). Visible tumor volume was measured on the indicated days
with calipers. At the termination of the experiment, tumors were excised and
weighed. For generation of SIRT4 mutant mice, chimeric mice were mated
with NIH Black Swiss females (Taconic) to screen for germline transmission.
Male mice bearing germline transmission were mated with female FVB EIIa-
Cre mice to generate whole body exons 3 and 4 deletion of the Sirt4 gene. All
experiments were approved by the Animal Care and Use Committee of the
National Institute of Diabetes, Digestive and Kidney Diseases.
Histological Analysis
Tumors were dissected from mice and fixed in 10% neutral-buffered formalin
(Sigma) at room temperature overnight and placed in 70% ethanol for at least
one day. Then, the tumor tissues were dehydrated through a graded alcohol
series, xylene and paraffin, and then embedded in paraffin. Sections of 5 mm
were cut and stained by hematoxylin and eosin (H&E).FlowCytometricMeasurement of Cell Death andBrdU Incorporation
Cells at less than 80% confluency were treated with DNA damage agents.
After treatments, cells were harvested by trypsinization, pelleted by centrifuga-
tion, and resuspended in PBS containing 3% fetal bovine serum. The
measurement of cell death was performed by flow cytometry using propidium
iodide (PI) staining, as previously described. The incorporation of BrdU into the
genomic DNA was measured with BrdU Flow Kit (BD PharMingen) according
to the manufacturer’s instructions.
gH2AX Immunofluorescence
Cells grown on coverslips or eight-well microscopy slides were fixed for
20 min with 4% paraformaldehyde and permeabilized by 0.1% Triton X-100
for 3 min. Cells were then incubated overnight at 4 with mouse monoclonal
antibodies against gH2AX (Ser139) (Millipore, 1:200 dilution) followed by
goat anti-mouse immunoglobulin G-FITC (Santa Cruz, 1:300). Cell images
were taken under a Zeiss microscope using a 63X objective and analyzed
for foci/nucleus.
Glutamine and Glucose Measurements
Glutamine, ammonia, glucose, and lactate levels in culture media were
measured using the BioProfile FLEX analyzer (Nova Biomedical), as previously
described (Finley et al., 2011). Briefly, fresh media were added to a six-well
plate of cells, and metabolite levels in the media were measured 6–9 hr later
and normalized to the number of cells in each well.
Metabolites Profiling
Metabolites were extracted and analyzed as previously described (Finley et al.,
2011). Briefly, SIRT4WT and KOMEFs were plated, thenmetabolites were ex-
tracted at 4 hr after 20 J/m2 UV exposure. Metabolite levels were normalized to
the total of all metabolites detected.
Statistical Analysis
Unpaired two-tailed Student’s t tests were performed unless otherwise
noted. All experiments were performed at least two or three times. For the
tumor incidence and survival study, the log rank (Mantel-Cox) test was
performed.
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